This article is more than 5 years old. Information may no longer be current.
FDA approves receiverless Dexcom CGM
Click Here to Manage Email Alerts
The FDA today approved the Dexcom G5 Continuous Glucose Monitoring System, according to a company press release.
The new system is the first fully mobile continuous glucose monitor (CGM) system approved for use in adults and children as young as 2 years. Glucose data are directly transmitted to a smartphone by wireless Bluetooth technology, freeing users from the need to carry a separate receiver. Data will be directly transmitted to iOS-enabled devices and Android applications are expected early next year.
“Dexcom is rapidly advancing technology for continuous glucose monitoring devices to improve diabetes management,” Kevin Sayer, president and CEO of Dexcom, said in the release. “Since January, the company has introduced the G4 PLATINUM CGM with ‘Share,’ apps to enable the first CGM on the Apple Watch and now the Dexcom G5 Mobile CGM. These advances are making diabetes management more convenient and flexible than ever before. We are excited for the promise this new technology holds for patients and caregivers.”